Clinical pharmacology

  • ROZLYTREK inhibits all 3 subtypes of TRK (TRKA, TRKB, and TRKC) 1
  • ROZLYTREK inhibits ROS1 1

ROZLYTREK penetrates the blood-brain barrier and demonstrates antitumor activity in intracranial models 1

  • P-gp substrates are typically effluxed from the CNS by P-gp transporter proteins lining the blood-brain barrier 14
  • In vitro studies suggest that ROZLYTREK is not a substrate of P-gp, but M5, the major active metabolite of ROZLYTREK, is a substrate of P-gp 1
BCRP=breast cancer resistance protein; CNS=central nervous system; MRP=multidrug resistance-associated protein; P-gp=P-glycoprotein; ROS1=ROS proto-oncogene 1; TRK=tropomyosin receptor kinase.
ROZLYTREK Efficacy in NTRK Fusion-Positive Solid Tumors

Efficacy Across Tumor Types in Patients With NTRK Fusion-Positive Solid Tumors

View systemic efficacy data in patients with NTRK fusion-positive solid tumors, including response rates by tumor type

ROZLYTREK Efficacy in ROS1+ Patients

Efficacy in ROS1+ mNSCLC Patients

View efficacy data in ROS1+ patients

ROZLYTREK Financial Resources

Financial and Other Resources

Learn more about financial and other resources for ROZLYTREK